Our technologies

Engineering

X-Ray Phase Contrast Imaging for Enhanced Threat Detection and Composite Material Analysis

X-Ray Phase Contrast Imaging for Enhanced Threat Detection and Composite Material AnalysisAvailable for: Licensing and co-developmentSummaryProfessor Sandro Olivo and his team at University College London have developed a novel phase contrast x-ray technology with potential for improved image quality and enhanced diagnostic potential when applied to non-destructive testing, homeland security and material science applications. This

More info »

Biopharm

Leukocyte labelling for detecting inflammation

Available for: Exclusive/Non-Exclusive licensingSummaryInflammation plays a role in many diseases including sight-threatening diseases of the eye such as uveitis. Recently, inflammation has also been shown to drive the processes of pathological angiogenesis in Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). Current methods for monitoring inflammation have limits and include direct visualisation by endoscope, PET

More info »

Biopharm

New lentiviral platform eliminating packaging sequences from the transcribed DNA region

Available for: Exclusive/Non-exclusive LicensingSummaryAll lentiviral vectors described to date contain packaging sequences necessary for the viral RNA genome to be assembled into viral particles. These sequences are unnecessarily reverse transcribed into DNA and permanently integrate into target cells. The researchers at UCL Institute of Child Health have developed a lentiviral platform which does not reverse

More info »

Biopharm

Treatment of fibrosis with ALDH inhibitors

Treatment of fibrosis with ALDH inhibitorsAvailable for: Exclusive LicensingSummaryFibrosis is the formation of excess fibrous connective tissue in response to injury and inflammation. If it happens in response to injury it is also referred to as scarring. Fibrosis is associated with conditions such as cystic fibrosis, cirrhosis, mucous membrane pemphigoid (MMP), pulmonary fibrosis and scleroderma.

More info »

Biopharm

Novel Therapy for Polycystic Kidney Disease (PKD)

Available for: Exclusive/Non-Exclusive LicensingSummaryPolycystic kidney disease is the most common inherited cause of kidney failure, affecting 1 in 1000 adults and children worldwide. It is characterized by the growth of multiple cysts leading to loss of normal kidney structure and functions and often results in end-stage renal disease. The researchers at UCL Institute of Child

More info »

Biopharm

Silica Wool

Porous superhydrophobic/ superoleophillic material for oil-water separation and remediationAvailable for: Exclusive and Non-Exclusive LicensingSummaryThe technology comprises a porous material having both superhydrophobic and superoleophillic properties and is suitable for water-oil separation /filtration and remediation. Laboratory results achieved to date have used functionalised silica wool and have demonstrated high oil-water separation efficacy. The best performing solvent

More info »

Biopharm

Preventing amyloid fibril formation. The recently identified pathogenic D76N ß2 microglobulin variant which readily forms amyloid fibrils under physiological conditions in vitro is a crucial new tool for mechanistic studies and screening studies

We have characterized the first naturally occurring structural variant of human beta-2M, D76N, as the amyloid fibril protein in a family with a new phenotype of late onset, fatal, hereditary systemic amyloidosis (Valleix et al N Engl J Med). We have discovered a method suitable for the fibrillogenesis of this protein that is consistent with

More info »

Biopharm

H4R antagonists for uveitis and other inflammatory diseases

Available For: Exclusive LicensingSummaryHistamine is a pleiotropic mediator involved in a variety of physiological processes including neurotransmission, endocrine and vascular processes. It also plays a key role in inflammation and binding to one of its four receptors (H1R-H4R). Researchers at UCL Institute of Ophthalmology have shown that targeting H4R receptor in the central nervous system

More info »

Biopharm

Lrg-1 antagonists: Direct effect upon cancer cells

LRG1 antagonists for neovascularisation, cancer and aberrant scaring Available for: Exclusive/Non-exclusive licensing SummaryThe formation of new blood vessels by angiogenesis is a key feature of number of diseases including Age-related Macular Degeneration (AMD), Proliferative Diabetic Retinopathy (PDR), atherosclerosis, rheumatoid arthritis and cancer. Vascular Endothelial Growth Factors (VEGFs) and their receptors have been previously identified as

More info »

Biopharm

Modulating Sonic Hedgehog signalling for treatment of Autoimmune Disease and Inflammation

Available for: Exclusive/Non-exclusive licensingSummaryChronic inflammation plays role in diseases such as asthma, atopic skin conditions and cancer. On the molecular level, inflammation is driven by T-helper cells and researchers at UCL Institute of Child Health discovered that the Sonic Hedgehogpathway modulation can shift T-cell differentiation and modify the inflammatory response. This can have potential applications

More info »

View by:

Technology area:
Theme:
Market:
Search: